Close Menu

NEW YORK – Machine learning diagnostic firm Prevencio announced Tuesday it is collaborating with Seattle Children's Research Institute to develop a blood test for Kawasaki disease.

The institute will provide Prevencio with blood samples and the firm will use its HART AI platform to develop a blood test for the disease. Under the agreement, Prevencio will retain exclusive global rights to the test. The firm will use its laboratory partner Myriad RBM to measure proteins in the blood samples.

Additional terms of the deal were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.

Sponsored by
LGC SeraCare Life Sciences

As we pass the one-year anniversary of both the COVID-19 pandemic and the first Emergency Use Authorized SARS-CoV-2 PCR detection assays, there remains significant opportunity for clinical laboratories to advance testing and support improved patient management.

Sponsored by

This webinar will present the details of a COVID-19 saliva screening program that has been implemented at more than 90 different colleges, universities, private schools, and nursing homes across New York state.